Wednesday, Sept. 1

Room A

Time: 8:30-8:35

Welcome Address:

Takashi Nakano, Conference Chair IMIG 2010
(Hyogo College of Medicine, Japan)

Time: 8:30-8:40

President’s address:

Hedy Kindler
(University of Chicago, USA)

Time: 8:40-9:00

Introduction to IMIG Web site:

Courtney Broaddus
(University of California, San Francisco General Hospital, USA)

Time: 9:00-10:20

General Session: Epidemiology

Chair: Jim teWaterNaude
(Asbestos Relief Trust, South Africa and School of Public Health, University of Cape Town, South Africa)

Yoshiharu Aizawa
(Kitasato Univ. School of Medicine, Japan)

S01-1 Global epidemiology of malignant pediatric mesothelioma
Sergey Kashanskiy
(The laboratory of occupational medicine, Yekaterinburg Medical Research Center, Russia)

S01-2 Epidemiologic and clinicopathologic analysis of malignant mesothelioma in Korea during past four years (from 2006 to 2009)
Soon-Hee Jung
(Department of Pathology, Yonsei University Wonju College of Medicine, Korea)

S01-3 Keynote
Mesothelioma, a global panoramic view
Ken Takahashi
(University of Occupational and Environmental Health, Japan)

S01-4 Keynote
Epidemiology of mesothelioma in Egypt and Mediterranean countries
Rabab Gaafar
(Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt)

S01-5 Keynote
The epidemiology of 3 asbestos ores and 3 disease profiles in a South African compensation database
Jim teWaterNaude
(Asbestos Relief Trust, South Africa and School of Public Health, University of Cape Town, South Africa)
Panel Discussion: Asbestos in the world

Chair: Bruce Robinson
(National Centre for Asbestos Related Diseases, University of Western Australia, Australia)
Ken Takahashi
(Department of Environmental Epidemiology, University of Occupational and Environmental Health, Japan)

Introduction (Chairperson)

PD01-1 The magic stone: Asbestos between history and myth
Claudio Bianchi
(Center for the Study of Environmental Cancer - Italian League against Cancer, Italy)

PD01-2 Impact of malignant mesothelioma in Taiwan: A 27-year review of population-based cancer registry data
Lukas Lee
(Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Taiwan)

PD01-3 Study on the relationship between exposure to asbestos and asbestos-related diseases in Vietnam
Tran Thi Ngoc Lan
(Environment Health Management Agency, Vietnam Ministry of Health, Vietnam)

PD01-4 Pleural mesothelioma rates in South Africa: trends 1995-2006
Spooponki Kgalamono
(The National Institute for Occupational Health, Johannesburg, South Africa)

PD01-5 Future burden of malignant mesothelioma in Western Australia
Nicholas de Klerk
(Centre for Child Health Research, University of Western Australia, Australia)

PD01-6 Mesothelioma in England - results from the National Lung Cancer Audit 2006-2009
Mick Peake
(Royal College of Physicians, UK)

Time: 13:00-14:30

General Session: First-line treatment

Chair: Jan van Meerbeeck
(Department of Respiratory Medicine and Thoracic Oncology, Ghent University Hospital, Belgium)
Akihiko Gemma
(Division of Pulmonary Medicine, Infectious Diseases, and Oncology, Department of Internal Medicine, Nippon Medical School, Japan)

S06-1 Inoperable malignant pleural mesothelioma: Phase II study of 1st line treatment with carboplatin and vinorelbine
Jens Sorensen
(Department of Oncology, Finsen Centre, National University Hospital, Denmark)
S06-2 Anti-mesothelin immunotoxin SS1P plus cisplatin and pemetrexed for first line treatment of mesothelioma
Raffit Hassan
(Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA)

S06-3 Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma (MPM)
Giovanni Ceresoli
(Oncology Unit, Cliniche Humanitas Gavazzeni, Italy)

S06-4 IFCT-GFPC-0701 MAPS trial, a multi-center randomized phase II-III trial of pemetrexed - cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma: preliminary results of the phase II trial
Arnaud Scherpereel
(Pulmonary and Thoracic Oncology, University Hospital (CHRU) of Lille, France)

S06-5 Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study
Shinichi Nishiuma
(Eli Lilly Japan, Japan)

S06-6 First line chemotherapy for malignant pleural mesothelioma
Keynote
Jan van Meerbeeck
(Department of Respiratory Medicine and Thoracic Oncology Ghent University Hospital, Belgium)

Time: 14:30-16:00

General Session: Second-line treatment

Chair: Christopher Lee
(Anatomical Pathology, BC Cancer Agency-Fraser Valley Centre, Canada)
Mikio Oka
(Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Japan)

S10-1 VANTAGE 014: Vorinostat in patients with advanced malignant pleural mesothelioma (MPM) previously treated with pemetrexed and either cisplatin or carboplatin: A phase III, randomized, double-blind, placebo-controlled trial
Lee Krug
(Memorial Sloan-Kettering Cancer Center, USA)

S10-2 Open label randomized phase III maintenance study of thalidomide (arm A) vs. observation (arm B) in patients with MPM after treatment with cisplatin and pemetrexed: interim report
Paul Baas
(The Netherlands Cancer Institute, Netherlands)
S10-3 Randomized, multicentre phase IIIb study of ranpirnase + doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM)
Joachim von Pawel
(Asklepios Fachkliniken Muenchen-Gauting, Germany)

S10-4 Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM)
Paolo Zucali
(Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Italy)

S10-5 Platinum-based doublet chemotherapy in pretreated Malignant Pleural Mesothelioma (MPM) patients: a mono-institutional experience
Giulia Pasello
(Medical Oncology Department of Istituto Oncologico Veneto, IRCCS, Italy)

S10-6 Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter study
Paolo Zucali
(Department of Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy)

S10-7 Keynote Beyond first-line systemic therapy for MPM
Christopher Lee
(Medical Oncology, BC Cancer Agency-Fraser Valley Centre, Canada)

Time: 16:20-17:30

General Session: Molecular target therapy

Chair: Hedy Kindler
(Section of Hematology/Oncology, University of Chicago, USA)
Ichiro Kawase
(Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan)

S13-1 Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma
Anna Nowak
(School of Medicine and Pharmacology, University of Western Australia, Australia)

S13-2 A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma(MM): CALGB 30601
Arkadiusz Dudek
(University of Minnesota, USA)

S13-3 Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM)
Lee Krug
(Memorial Sloan-Kettering Cancer Center, USA)

S13-4 Tissue response in patients with MPM after treatment with cisplatin, pemetrexed and axitinib: First results of a feasibility study
Wieneke Buikhuisen
(Netherlands Cancer Institute, The Netherlands)
General Session: Clinical tumor markers: the state of the art

Chair: Sakari Knuutila
(Department of Pathology, Haartman Institute, University of Helsinki, Finland)
Koichi Kaneko
(Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Japan)

S02-1 Circulating microRNAs as markers of malignant mesothelioma
Glenn Reid
(Asbestos Diseases Research Institute, Bernie Banton Centre, University of Sydney, Australia)

S02-2 Glycomics identifies diagnostic biomarkers and immuno-therapeutic targets of malignant mesothelioma
Margaret Huflejt
(Department of Cardiothoracic Surgery, New York University, School of Medicine, USA)

S02-3 Malignant pleural mesothelioma: Potential biological role of fibroblast growth factor (FGF) -9
Ai Ling Tan
(Department of Medicine and Pharmacology, University of Western Australia and Sir Charles Gairdner Hospital, Australia)

S02-4 Diagnostic markers of mesothelioma: A systematic review
Jacobus Burgers
(Department of Thoracic Oncology, The Netherlands Cancer Institute, The Netherlands)

S02-5 Prognostication of mesothelioma: Isolation without integration
Harvey Pass
(Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, NYU Langone Medical Center, USA)

General Session: Biomarkers

Chair: Marcello Deraco
(Department of Surgery-Peritoneal Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy)
Tomoyuki Goya
(Department of Surgery, Kyorin University School of Medicine, Japan)

S04-1 Soluble biomarkers for Mesothelioma – beyond diagnosis
Jenette Creaney
(National Research Centre for Asbestos Related Diseases, UWA, Australia)

S04-2 Sequential gene expression ratio-based diagnostic tests distinguish malignant pleural mesothelioma from other thoracic malignancies
Assunta De Rienzo
(Division of Thoracic Surgery and the International Mesothelioma Program, Brigham and Women’s Hospital, and Harvard Medical School, USA)
S04-3 An in vivo platform for biomarker validation in malignant pleural mesothelioma
Elliot Servais
(Memorial Sloan-Kettering Cancer Center, USA)

S04-4 Circulating endothelial cells (CECs) in the diagnosis of malignant pleural mesothelioma (MPM)
Fumihiro Tanaka
(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

S04-5 ERCC1: with our prognostic or predictive impact for malignant pleural mesothelioma
Isabelle Opitz
(Division of Thoracic Surgery, University Hospital Zurich, Switzerland)

S04-6 Immunohistochemical detection of ERCC1 and class III β-tubulin in 54 malignant pleural mesotheliomas treated with cisplatin and vinorelbine: Association with treatment response and survival
Zarah Zimling
(Department of Pathology, National University Hospital, Denmark)

Time: 13:00-14:00

General Session: SMRP & MPF
Chair: Eiji Shimizu
(Division of Medical Oncology and Molecular Respiriology, Tottori University, Faculty of Medicine, Japan)
Rabab Gaafar
(Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt)

S07-1 Soluble mesothelin related protein (SMRP) in malignant pleural mesothelioma (MPM)
Rabab Gaafar
(Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt)

S07-2 Soluble mesothelin and megakaryocyte potentiating factor: Prognostic value and impact of covariates on the diagnostic performance
Kevin Hollevoet
(Department of Respiratory Medicine, Ghent University Hospital, Belgium)

S07-3 Combination of serum mesothelin and plasmatic osteopontin in the diagnosis of malignant pleural mesothelioma
Rudy Foddis
(Division of Occupational and Preventive Medicine, University Hospital of Pisa, Italy)

S07-4 SMRP expression in a cohort of australian asbestos-exposed power industry workers
AD LaMontagne
(McCaughhey Centre, Melbourne School of Population Health, University of Melbourne, Australia)
S07-5  Low serum SMRP (soluble mesothelin-related peptide) identifies patients with extended survival for malignant pleural mesothelioma
Lindsay Almquist  
(Masonic Cancer Center, University of Minnesota, USA)

Time: 14:00-15:00

**General Session: PET scan in MPM Imaging**

**Chair:** Shuji Adachi  
(Department of Radiology, Hyogo Cancer Center, Japan)
Gunnar Hillerdal  
(Lung Department, Karolinska Hospital, Sweden)

S08-1  Functional MR tools for diagnosing malignant pleural mesothelioma
Johan Coolen  
(Department of Radiology, University Hospitals Leuven, Belgium)

S08-2  Role of PET/CT in staging and surgery for malignant pleural mesothelioma
Cosimo Lequaglie  
(Thoracic Surgery, IRCCS Ospedale Oncologico Rionero in Vulture, Italy)

S08-3  '18F-Fluorothymidine positron emission tomography (FLT PET) imaging in malignant pleural mesothelioma (MPM)
Roslyn Francis  
(Department of Nuclear Medicine/ WA PET Centre, Sir Charles Gairdner Hospital, Australia)

S08-4  Comparison of dynamic contrast enhanced MRI (DCE-MRI) parameters with integrated PET-CT (TGV and SUVmax) and serum mesothelin in the baseline assessment of malignant pleural mesothelioma (MPM)
Clare Hooper  
(University of Bristol, Pleural Clinical Trials Unit, Southmead Hospital, UK)

S08-5  Computerized measurement of malignant pleural mesothelioma
William Sensakovic  
(Committee on Medical Physics, The University of Chicago, Chicago, USA)

Time: 15:00-16:00

**General Session: Peritoneal mesothelioma**

**Chair:** Paul Sugarbaker  
(Washington Cancer Institute, USA)
Toshikazu Yusa  
(Department of Chest Surgery, Chiba Rosai Hospital, Japan)

S11-1  A novel tumor node metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma based on outcome analysis of a multi-institutional database
Tristan Yan  
(The Baird Institute for Applied Heart and Lung Surgical Research, Australia)
Clinical utility of positron emission tomography with $^{18}$F-FDG for malignant peritoneal mesothelioma

Anna Domenech
(Department of Radiology, Columbia College of Physicians and Surgeons, USA)

1st line treatment with platinum and vinorelbine in malignant peritoneal mesothelioma

Jens Sorensen
(Dept. Oncology, Finsen Centre, National University Hospital, Denmark)

Intraperitoneal pemetrexed combined with intravenous cisplatin: A well tolerated adjuvant treatment for diffuse malignant peritoneal mesothelioma

Paul Sugarbaker
(Washington Cancer Institute, USA)

Time: 16:20-17:30

Workshop: Peritoneal mesothelioma—Clinical and translational research—

Chair: Luciano Mutti
(Department of Medicine, Local Health Unit 11, Vercelli, Italy)
Naohiko Inase
(Department of Integrated Pulmonology, Tokyo Medical and Dental University, Japan)

Clinical management of diffuse malignant peritoneal mesothelioma

Paul Sugarbaker
(Washington Cancer Institute, Washington, DC)

Cancelled

Identification and validation of new prognostic biomarkers and therapeutic targets

Nadia Zaffaroni
(Departments of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy)

Translation of new prognostic biomarkers and therapeutic targets in clinical practice

Marcello Deraco
(Department of Surgery-Peritoneal Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy)
Room B2

Time: 9:00-10:20

General Session: Biology Pathogenesis

Chair: Steven Albelda
(Thoracic Oncology Gene Therapy Program, University of Pennsylvania Medical Center, USA)
Takemi Otsuki
(Department of Hygiene, Kawasaki Medical School, Japan)

S03-1 The expression of DPP10, a novel chimera gene identified by second generation sequencing of tumor genome, is associated with outcome in mesothelioma
Assunta De Rienzo
(Division of Thoracic Surgery and the International Mesothelioma Program, Brigham and Women’s Hospital, and Harvard Medical School, USA)

S03-2 Next-generation transcriptome sequencing identifies novel fusion transcripts in malignant pleural mesothelioma
Lingsheng Dong
(Division of Thoracic Surgery and the International Mesothelioma Program, Brigham and Women’s Hospital, and Harvard Medical School, USA)

S03-3 Specific syndecan-1 domains regulate mesothelioma cell growth and migration
Fang Zong
(Department of Laboratory Medicine, Karolinska Institutet, Sweden)

S03-4 Mesothelin expression promotes invasive phenotype and matrix metalloproteinase secretion in pleural mesothelioma
Elliot Servais
(Memorial Sloan-Kettering Cancer Center, USA)

S03-5 Transforming growth factor beta signaling in malignant mesothelioma growth and collagen production
Bahareh Badrian
(Lung Institute of Western Australia, Department of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Australia)

S03-6 Genome-wide profile of pleural mesothelioma versus parietal pleura: Confirmation of the gene portrait of mesothelioma
Oluf Roe
(Dept. of Oncology, St. Olavs Hospital, University Hospital of Trondheim, Norway)
Time: 10:40-12:00

**General Session: Novel targets**

**Chair:** Raffit Hassan  
(Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health, USA)  
*Nobuyuki Katakami*  
(Department of Medical Oncology, Biomedical Research and Innovation, Japan)

**S05-1**  
*Anti-Mesothelin Immunotoxin SS1P Plus Cisplatin And Pemetrexed For First Line Treatment of Mesothelioma*  
Raffit Hassan  
(Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA)

**S05-2**  
*Activity and resistance to the pan-BCL-2 antagonist Obatoclax in malignant pleural mesothelioma*  
Niall McTavish  
(Centre for Cancer Research and Cell Biology, Queens University, UK)

**S05-3**  
*Polycomb repressive complex-2 is a novel target for mesothelioma therapy*  
Clinton Kemp  
(Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA)

**S05-4**  
*Inhibition of mTOR by temisolimus is active against malignant mesothelioma in vitro and in vivo and synergizes with chemotherapy*  
Mir Hoda  
(Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Austria)

**S05-5**  
*The role of the hedgehog pathway in the development of malignant mesothelioma*  
Steven Mutsaers  
(Lung Institute of Western Australia and Center for Asthma, Allergy and Respiratory Research, Department of Medicine, University of Western Australia, Australia)

**S05-6**  
*Y-Box-binding protein 1: A potential therapeutic target in malignant mesothelioma*  
Michaela Kirschner  
(Asbestos Diseases Research Institute, Bernie Banton Centre, University of Sydney, Australia)

Time: 13:00-14:00

**Difficult Cases: Pathology-Ⅱ: Difficult cases: ask the expert**

**Chair:** Yuichi Ishikawa  
(The Cancer Institute, Japanese Foundation for Cancer Research, Japan)  
Françoise Galateau-Sallé  
(Département de Pathologie, University of Caen, France)

**DC02-1**  
*A rare case of papillary well-differentiated peritoneal mesothelioma with transition into diffuse malignant mesothelioma.*  
Marcello Deraco  
(Departments of Surgery-Peritoneal Malignancy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy)
DC02-2 Experiences of cytology evidence for early recognizing occupational malignant mesothelioma in Taiwan
Lukas Lee
(Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Taiwan)

DC02-3 KG case abstract for IMIG 2010 Difficult Cases: Ask the Experts
Andrea Wolf
(Division of Thoracic Surgery, Brigham and Women’s Hospital, USA)

Time: 14:00-15:00

General Session: Thoracoscopy

Chair: Hans Hoffmann
(Department of Surgery, Thoraxklinik, University of Heidelberg, Germany)
Yoshiki Ishii
(Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Japan)

S09-1 Keynote
Thoracoscopy in mesothelioma
Hans Hoffmann
(Department of Surgery, Thoraxklinik, University of Heidelberg, Germany)

S09-2 A new electrocautery pleural biopsy technique using an insulated tip diathermic knife during semirigid pleuroscopy
Shinji Sasada
(Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan)

S09-3 Narrow band imaging: A new technology for the diagnosis of malignant pleural mesothelioma
Atsuko Ishida
(Division of Respiratory and Infectious Diseases, Department of Internal Medicine, St Marianna University School of Medicine, Japan)

S09-4 Thoracoscopy combined with autofluorescence imaging and narrow band imaging for the diagnosis of malignant pleural mesothelioma
Akihiro Yasumitsu
(Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan)

Time: 15:00-16:00

General Session: Radiation biology & Radiotherapy-I

Chair: Aaron Allen
(Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, USA)
Keiko Shibuya
(Department of Radiation Oncology and Image Applied Therapy, Kyoto University Hospital, Japan)

S12-1 Keynote
IMRT provides excellent local control in pleural mesothelioma with and without surgery
Aaron Allen
(Department of radiation oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, USA)
S12-2  Acute toxicities observed with neoadjuvant short accelerated hemithoracic radiotherapy (RT) followed by extra-pleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM): preliminary results
B.C. John Cho
(Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Canada)

S12-3  Liver toxicity following extrapleural pneumonectomy and adjuvant three-dimensional conformal radiation therapy for treatment of malignant pleural mesothelioma
Robert Lin
(Department of Radiation Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Australia)

S12-4  Hypofractionated palliative radiotherapy for malignant mesothelioma using helical tomotherapy
Rufus Scrimger
(Department of Oncology, University of Alberta, Canada)

Time: 16:20-17:30

General Session: Radiation biology & Radiotherapy-II
Chair: Malcolm Feigen
(Radiation Oncology Centre, Austin Health, Heidelberg West, Victoria, Australia)
Norihiko Kamikonya
(Department of Radiology, Hyogo College of Medicine, Japan)

S14-1  Feasibility of pleural intensity-modulated radiation therapy (IMRT) for malignant pleural mesothelioma (MPM)
Marjorie Zauderer
(Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, USA)

S14-2  Trimodality treatment for malignant pleural mesothelioma: Intensity-modulated radiotherapy after extrapleural pneumonectomy
Naoya Yamasaki
(Division of Surgical Oncology, Nagasaki University Graduate School of Biochemical Sciences, Japan)

S14-3  Feasibility and efficacy of trimodality treatment with intensity modulated radiation therapy for malignant pleural mesothelioma - preliminary assessment
Kenichi Okubo
(Thoracic Surgery, Tokyo Medical and Dental University, Japan)

S14-4  Hemithoracic irradiation in malignant mesothelioma patients (MPM); the Amsterdam experience and a review of the literature
Paul Baas
(The Netherlands Cancer Institute, the Netherlands)

S14-5  Keynote
Major advances in locoregional control and palliation of mesothelioma using high dose radiotherapy with new technologies and ^18F-FDG PET scanning
Malcolm Feigen
(Radiation Oncology Centre, Austin Health, Heidelberg West, Victoria, Australia)
Annex Hall

Time: 9:00-10:20

Round-table Discussion: Pathology-Ⅰ: new insights

**Chair:** Victor Roggli  
(Department of Pathology, Duke University Medical Center, USA)  
Kenzo Hiroshima  
(Department of Pathology, Tokyo Women’s Medical University Yachiyo Medical Center, Japan)

**RD01-1** Prognostic significance of promoter methylation of \(p16\) in pleural mesothelioma  
Kenzo Hiroshima  
(Department of Pathology, Tokyo Women’s Medical University Yachiyo Medical Center, Japan)

**RD01-2** Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma  
Brock Christensen  
(Department of Pathology and Laboratory Medicine, Brown University, USA)

**RD01-3** Stromal chronic inflammatory response is a significant predictor of survival in epithelioid diffuse malignant pleural mesothelioma (DMPM)  
Kei Suzuki  
(Memorial Sloan-Kettering Cancer Center, USA)

**RD01-4** Significance of pleomorphic, solid, and micropapillary subtypes in epithelioid diffuse malignant pleural mesothelioma (DMPM)  
Kyuichi Kadota  
(Department of Pathology, Memorial Sloan Kettering Cancer Center, USA)

**RD01-5** Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines  
Vishwa Jeet Amatya  
(Department of Pathology, Hiroshima University Graduate School of Biomedical Sciences, JAPAN)

**RD01-6** High prevalence of atypical mesothelial proliferation in extrapleural pneumonectomy specimens; further evidence of a potential precursor lesion to invasive mesothelioma  
Leona Doyle  
(Department of Pathology, Brigham and Women’s Hospital, USA)

**RD01-7** Napsin A is helpful in separating adenocarcinoma of the lung from malignant mesothelioma  
Andras Khoor  
(Department of Laboratory Medicine and Pathology, Mayo Clinic, USA)

Round-table discussion
**Workshop: Cytopathology-How reliable is it?-**

**Chair:** Andrew Churg  
(Department of Pathology, University of British Columbia, Canada)  
**Yoshihiro Matsumoto**  
(Department of Surgical Pathology, Hokkaido University Hospital, Japan)

**WS01-1**  
**Keynote**  
Cytopathology-How reliable is it?
Françoise Galateau-Sallé  
(MESOPATH- Center-MESONAT Registry-INSERM ERB, France)

**WS01-2**  
How to make a definitive diagnosis of mesothelioma by effusion cytology?  
Shotaro Maeda  
(Department of Pathology, Tama-Nagayama Hospital, Nippon Medical School, Japan)

**WS01-3**  
Diagnostic significance of \(p16^{NK4A}\) loss in molecular cytology of early malignant pleural mesothelioma  
Tohru Tsujimura  
(Department of Pathology, Hyogo College of Medicine, Japan)

**WS01-4**  
Cytopathology of desmoplastic malignant mesothelioma (DMM)  
Sadayuki Hiroi  
(Department of pathology and Laboratory Medicine, National Defense Medical College, Japan)

**WS01-5**  
Correlation of pleural fluid cytological yield and visceral pleural invasion in patients with malignant pleural mesothelioma  
Valentina Pinelli  
(Pulmonary Division of Spedali Civili Brescia, Italy)

**WS01-6**  
Differential diagnosis of malignant mesothelioma and reactive mesothelial cell proliferation for cytology and biopsy  
Noriko Kimura  
(Department of Clinical Research Pathology Section, National Hospital Organization Hakodate Hospital, Japan)

**Workshop: Molecular oncogenesis**

**Chair:** Yoshitaka Sekido  
(Division of Molecular Oncology, Aichi Cancer Center Research Institute, Japan)  
**Courtney Broaddus**  
(University of California, San Francisco Chief, Division of Pulmonary and Critical Care Medicine San Francisco General Hospital, USA)

**WS02-1**  
**Keynote**  
Signalling transduction and survival pathways in mesothelial carcinogenesis  
Luciano Mutti  
(Department of Medicine, Local Health Unit 11, Vercelli, Italy)

**WS02-2**  
**Keynote**  
Inactivation of LATS2 indicates frequent dysregulation of the Merlin-Hippo signaling pathway in malignant mesothelioma cells  
Yoshitaka Sekido  
(Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan)
WS02-3 Genomic alterations in asbestos-related lung cancer and malignant mesothelioma
Penny Nymark
(Finnish Institute of Occupational Health, Finland)

WS02-4 Deep sequencing of mesothelioma genome DNA reveals chromosomal rearrangement as the dominant mutation
Raphael Bueno
(Division of Thoracic Surgery and the International Mesothelioma Program, Brigham and Women’s Hospital, and Harvard Medical School, USA)

WS02-5 Integrated genomic analysis reveals BRCA1-associated Protein 1 (BAP1) as a commonly mutated gene in malignant pleural mesothelioma (MPM)
Matthew Bott
(Memorial Sloan-Kettering Cancer Center, USA)

Time: 14:30-16:00

Workshop: Tumor microenvironment & Oncogenesis
Chair: Yoichi Nakanishi
(Department of Clinical Medicine, Faculty of Medical Sciences, Research Institute for Diseases of the Chest, Kyushu University, Japan)
Dean Fennell
(Center for Cancer Research and Cell Biology, The Queen’s University of Belfast, UK)

WS03-1 Introduction to the tumour microenvironment session
Marie-Claude Jaurand
(INSERM, UMR 674, Paris, Descartes, France)

WS03-2 Extracellular PDGF—D promotes migration of malignant mesothelioma
Takahiro Yaguchi
(Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Japan)

WS03-3 Epigenetic silencing of microRNA-34b/c plays a pivotal role in the pathogenesis of malignant pleural mesothelioma
Shinichi Toyooka
(Department of Cancer and Thoracic Surgery, Okayama University, Japan)

WS03-4 Expression, mutation and functional analysis of paxillin in malignant pleural mesothelioma
Rifat Hasina
(Department of Medicine, The University of Chicago, USA)

WS03-5 Formation of 8-nitroguanine, a DNA lesion in the lung of asbestos-exposed mice in relation to inflammation-related carcinogenesis
Yusuke Hiraku
(Department of Environmental and Molecular Medicine, Mie University Graduate School of Medicine, Japan)

WS03-6 Proteomic analysis of the mechanism of action of DuP-697 in mesothelioma cells
Vijay Agarwal
(Cancer Biology Proteomics Group, Postgraduate Medical Institute, University of Hull, UK)
Time: 16:20-17:30

**General Session: Screening**

**Chair:** Jenette Creaney  
(National Research Centre for Asbestos Related Disease, Sir Charles Gairdner Hospital, Australia)

**Kazuya Fukuoka**  
(Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan)

**S15-1**  
**Keynote**  
**New light on early diagnosis and therapy of asbestos-induced mesothelioma**  
Okio Hino  
(Department of Pathology and Oncology, Juntendo University School of Medicine, Japan)

**S15-2**  
**Low-dose computed tomography as a screening tool for malignant pleural mesothelioma and early lung cancer in asbestos exposed individuals: The Toronto Experience**  
Demetris Patsios  
(Department of Medical Imaging, University Health Network, Mount Sinai and Women’s College Hospital, Canada)

**S15-3**  
**Japanese general screening study for asbestos-related diseases (JG SARD study): Preliminary results**  
Kazuto Ashizawa  
(Clinical Oncology Center, Nagasaki University Hospital, Japan)

**S15-4**  
**Research in asbestos disease-affected communities - Can research process aid social healing?**  
AD LaMontagne  
(McCaughey Centre, Melbourne School of Population Health, University of Melbourne, Australia)

**S15-5**  
**Longitudinal stability and screening value of mesothelioma biomarkers in an asbestos-exposed population**  
Kevin Hollevoet  
(Department of Respiratory Medicine, Ghent University Hospital, Belgium)

**S15-6**  
**Serum SMRP (soluble mesothelin-related peptide) is determined by tumor MSLN methylation status in malignant pleural mesothelioma: implications for screening studies**  
Heather Nelson  
(Masonic Cancer Center, University of Minnesota, USA)